The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Escitalopram Therapy for Major Depression and Anxiety Disorders
Abstract
Background: Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability. Objective: To assess (he tolerability and safety of escitalopram through analysis of all randomized controlled clinical trials in major depressive disorder and anxiety disorders. Methods: Analyses of tolerability were based on data from all available randomized, double-blind, controlled studies completed by December 2006 in which escitalopram was compared with placebo or active compounds (citalopram, fluoxetine, paroxetine, sertraline, venlafaxine). Adverse events (AEs) that occurred more frequently with escitalopram than with placebo were listed, and tolerability and safety were evaluated. Results: Nausea was the only AE with an incidence greater than or equal to 10% and 5 percentage points greater than with placebo during short-term treatment. In general, AEs were mild to moderate in severity. AEs related to sexual dysfunction were similarly frequent with escitalopram and Citalopram, but were higher with paroxetine. No suicide occurred among escitalopram-treated patients, and there were no significant differences between escitalopram and placebo in incidence of suicidal behavior, measured by self-harm and suicidal thoughts. The 8 week withdrawal rate due to AEs was higher with escitalopram than with placebo (7.3% vs 2.8%; p < 0,001) but lower than with paroxetine (6.6% vs 9.0%; p < 0.01) or venlafaxine (6.1% vs 13.2%; p < 0.01) (Fisher's Exact test, 2 tailed). Compared with paroxetine, escitalopram resulted in significantly fewer discontinuation symptoms (average increase in Discontinuation Emergent Signs and Symptoms Scale of 1.6 vs 3.9; p < 0.01). There were no clinically relevant changes in clinical laboratory values in patients treated with escitalopram. Mean weight change after 6 months of treatment with escitalopram (0.58 ± 2.63 kg) was similar to that with placebo (0.15 ± 2.33 kg). The incidence of cardiovascular events was similar to that with placebo. The risk of AEs was no higher in special patient populations, such as the elderly (≥65 y of age) or those with hepatic dysfunction. Conclusions: Based on data from randomized controlled trials involving more than 4000 escitalopram-treated patients, escitalopram (10–20 mg/day) is safe and well tolerated in short- and long-term treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Time of Implantation of the Conceptus and Loss of Pregnancy
Wilcox, A. J., Baird, D. D., & Weinberg, C. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402304 · Cited by 1,081
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140
Self-citationEscitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Executive Dysfunction, Heart Disease Burden, and Remission of Geriatric Depression
Alexopoulos, G. S., Kiosses, D. N., Murphy, C., & Heo, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300557 · Cited by 117
Baldwin, D. S., Cooper, J. A., Huusom, A. K. T., & Hindmarch, I. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194377.88330.1d · Cited by 100
Self-citation
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
Self-citationEscitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
Baldwin, D. S., Asakura, S., Koyama, T., Hayano, T., Hagino, A., Reines, E., & Larsen, K. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.013 · Cited by 36
Self-citation
Metadata
- Authors
- Baldwin, D. S., Reines, E. H., Guiton, C., & Weiller, E.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2007-10
- Volume
- 41
- Issue
- 10
- Pages
- 1583-1592
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2155724210
- Cited by
- 228
- References
- 11
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram Therapy for Major Depression and Anxiety Disorders. https://app.cochat.ai/papers/10.1345/aph.1k089
- The paper
- Baldwin, D. S., Reines, E. H., Guiton, C., & Weiller, E. (2007). Escitalopram Therapy for Major Depression and Anxiety Disorders. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1k089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.